Nov 23, 2021

Isogenica is excited to announce its corporate sponsorship at PEGS  November 2-4th 2021

Isogenica is delighted to announce its successful attendance at PEGS Europe 2021 as Corporate Sponsors, were members of the Isogenica Team attended in person at Barcelona.

Isogenica’s Senior Scientist of Assay Development, Lurdes Duarte, hosted a presentation on the latest data on Isogenica’s VHH as next generation therapeutics. 

If Isogenica VHH antibodies have application in your discovery projects or you would like to learn more about partnering with Isogenica, get in touch and we will be glad to schedule a meeting.

​If you missed the presentation, download our poster which summarises the key points discussed in Lurdes’ talk.

Further Information

Isogenica has developed LlamdA™ (single domain VHH) therapeutic antibodies from its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process.  Over the last four years Isogenica has entered into eight significant partnerships, leveraging its libraries, technologies and expertise to build a broad pipeline of programs that are now advancing into pre-clinical and early clinical development with our partners.”


Mandeep Sehmi,
Business Development

T +44 1799 533 680


Contact us